KYBELLA (deoxycholic acid) injection, also known as ATX-101, is the only FDA-approved drug that contours and improves the appearance of submental fullness due to submental fat.

KYBELLA is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

KYBELLA is a naturally-occurring molecule in the body that helps in the breakdown and absorption of dietary fat.

When injected, KYBELLA causes the destruction of fat cells. Those cells that were destroyed then cannot store or collect fat. Once you have achieved your goal, retreatment with KYBELLA is not expected.

KYBELLA is administered by injections into the fat in the desired area.

KYBELLA is very safe as it has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which over 1,600 have been treated with KYBELLA.

Production of KYBELLA is a highly controlled, quality-assured and validated, current Good Manufacturing Practices-compliant process to ensure patient safety.

Side effects may include swelling, bruising, pain, numbness, redness or formation of small areas of firmness. Care must be taken when injecting KYBELLA to avoid the risk of marginal mandibular nerve injury and dysphagia.